Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Baer

Showing results (341-350 of 628) with videos related to

Pageof 63
Sort By:
American Journal of Obstetrics and Gynecology|September 9, 2022
Assessing the robustness of results from clinical trials and meta-analyses with the fragility indexLifeng Lin, Aiwen Xing, Haitao Chu, et al.
Leukemia|April 1, 1990
Cytogenetic study of maturing granulocytes in bone marrow of patients with acute myelogenous leukemiaM R Baer, C Sreekantaiah, S N Jani Sait, et al.
International Journal of Hematology|March 6, 2013
Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practiceMartin S Tallman, George B McDonald, Laurie D DeLeve, et al.
Oncotarget|July 5, 2016
Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stressKshama A Doshi, Rossana Trotta, Karthika Natarajan, et al.
Journal of Comparative Effectiveness Research|August 15, 2015
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromesAmer M Zeidan, Franklin Hendrick, Erika Friedmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2007
The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2Weiguo Liu, Maria R Baer, Mary Jo Bowman, et al.
Oncology Reports|February 1, 2014
Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cellsYue-Li Sun, Priyank Kumar, Kamlesh Sodani, et al.
Molecular Cancer Therapeutics|November 18, 2003
Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance proteinTracy A Brooks, Hans Minderman, Kieran L O'Loughlin, et al.
Leukemia Research|May 13, 2008
Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancers and of cancers in multiple family membersAruna Padmanabhan, Julie A Baker, Gary Zirpoli, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 18, 2007
Concordance of pharmacogenetic polymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemiaJoli R Weiss, Maria R Baer, Christine B Ambrosone, et al.
Pageof 63

Showing results (341-350 of 628) with videos related to

Sort By:
Pageof 63
American Journal of Obstetrics and Gynecology|September 9, 2022
Assessing the robustness of results from clinical trials and meta-analyses with the fragility indexLifeng Lin, Aiwen Xing, Haitao Chu, et al.
Leukemia|April 1, 1990
Cytogenetic study of maturing granulocytes in bone marrow of patients with acute myelogenous leukemiaM R Baer, C Sreekantaiah, S N Jani Sait, et al.
International Journal of Hematology|March 6, 2013
Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practiceMartin S Tallman, George B McDonald, Laurie D DeLeve, et al.
Oncotarget|July 5, 2016
Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stressKshama A Doshi, Rossana Trotta, Karthika Natarajan, et al.
Journal of Comparative Effectiveness Research|August 15, 2015
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromesAmer M Zeidan, Franklin Hendrick, Erika Friedmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2007
The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2Weiguo Liu, Maria R Baer, Mary Jo Bowman, et al.
Oncology Reports|February 1, 2014
Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cellsYue-Li Sun, Priyank Kumar, Kamlesh Sodani, et al.
Molecular Cancer Therapeutics|November 18, 2003
Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance proteinTracy A Brooks, Hans Minderman, Kieran L O'Loughlin, et al.
Leukemia Research|May 13, 2008
Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancers and of cancers in multiple family membersAruna Padmanabhan, Julie A Baker, Gary Zirpoli, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 18, 2007
Concordance of pharmacogenetic polymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemiaJoli R Weiss, Maria R Baer, Christine B Ambrosone, et al.
Pageof 63